Navigation Links
Favrille Reports Fourth Quarter and Year End 2007 Financial Results
Date:2/19/2008

Analysis of Primary Endpoint for Phase 3 Registration Trial No Later Than

July 2008

SAN DIEGO, Feb. 19 /PRNewswire-FirstCall/ -- Favrille, Inc. (Nasdaq: FVRL), a biopharmaceutical company developing patient-specific, active immunotherapies for the treatment of cancer, today reported its financial results for the fourth quarter and year end 2007. For the quarter and year ended December 31, 2007, the Company reported net losses of $7.8 million, or $0.21 per share, and $43.1 million, or $1.28 per share, respectively, compared to $10.2 million, or $0.35 per share, and $40.5 million, or $1.49 per share, for the same periods in 2006.

(Logo: http://www.newscom.com/cgi-bin/prnh/20031013/LAM095LOGO)

"It is with great excitement and anticipation that we begin 2008 and approach the end of our Phase 3 clinical trial of Specifid(TM) (mitumprotimut-T, formerly FavId(R))," said John P. Longenecker, Ph.D., President and Chief Executive Officer of Favrille. "We are in the process of data collection and are on schedule for data cut off in April and completion of data analysis no later than July. The rate of disease progression continues to be very slow and we believe we have enrolled an optimal patient population to maximize prospects for demonstrating a clinical benefit in our Phase 3 trial."

Fourth Quarter and Year End 2007 Financial Review

Research and development expense was approximately $7.8 million and $34.9 million for the fourth quarter and year ended December 31, 2007, respectively, compared to approximately $7.7 million and $31.1 million for the same periods in 2006. The increase is primarily due to operating expenses, including salaries and stock-based compensation, associated with our commercial-scale manufacturing facility, and consulting and outside services to support our Specifid Phase 3 clinical trial. Total st
'/>"/>

SOURCE Favrille, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Favrille Announces $21.1 Million Registered Direct Offering
2. Favrille to Present at BIOCOM Investor Conference, Acumen BioFin Rodman & Renshaw Healthcare Conference and CIBC World Markets Healthcare Conference
3. Favrille to Host Conference Call and Live Webcast to Discuss Third Quarter 2007 Financial Results on October 25, 2007
4. Favrille to Present at BIO InvestorForum
5. Favrille to Present at AG Edwards Emerging Growth Conference and Wall Street Analyst Forum
6. Favrille CEO to Present at Bear Stearns Healthcare Conference
7. Favrille CEO to Present at NewsMakers in the Biotech Industry Investment Conference
8. JADO Reports Clinical Proof of Concept With Raft Modulator in Atopic Dermatitis
9. OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM) is Feasible in Acute Myocardial Infarction Patients, American Heart Journal Paper Reports
10. Senesco Technologies Reports Second Quarter Fiscal 2008 Financial Results
11. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 10, 2014 /PRNewswire-iReach/ -- Tute Genomics, the ... announced an agreement with Lineagen, Inc., to ... NextStep Dx PLUS.  Lineagen, focused on ... disorders, currently offers FirstStep Dx PLUS, ... used by healthcare providers as a first-line ...
(Date:7/10/2014)... April 15, 2014 -- According to the International ... nuclear security comes from terrorists acquiring sufficient quantities ... construct a crude nuclear explosive device. The IAEA ... trafficking have involved gram-level quantities, which can be ... According to a new study appearing this week ...
(Date:7/10/2014)... in the journal PNAS (Proceedings of the National ... day and sleep deprivation have a significant effect on ... at the best time of day to test for ... administering medicines effectively. , Researchers from the University of ... the links between sleep deprivation, body clock disruption and ...
(Date:7/10/2014)... The lithium-ion batteries that power our laptops and ... on a single charge with the help of a ... material to replace the graphite traditionally used in one ... 10 times the energy storage capacity of graphite. A ... electrode was published today in Nature Communications . ...
Breaking Biology Technology:Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 3Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 4Sensitive detection method may help impede illicit nuclear trafficking 2Time of day crucial to accurately test for diseases, new research finds 2Silicon sponge improves lithium-ion battery performance 2Silicon sponge improves lithium-ion battery performance 3
... weeks back, we took a look at the results of the ... that time, we saw that the Midwest had two states in the ... the top 20 states. I promised to circle back with you to ... the Midwest fared in this ranking. , ,The NIH falls under ...
... slowly getting over its shyness about asking for federal ... business executives is learning more about how ... Business Technology Transfer Conference at the Hilton Milwaukee ... programs, one (SBIR) designed to foster small business innovation, ...
... - Angel and venture investors have fewer secrets ... dispense some advice to early-stage executives during the National ... with scientific ties to the University of Wisconsin-Madison ... their products have a sustainable market advantage, and what ...
Cached Biology Technology:Midwest colleges strong contenders for NIH funds 2Midwest colleges strong contenders for NIH funds 3Midwest colleges strong contenders for NIH funds 4Midwest colleges strong contenders for NIH funds 5Wisconsin firms urged to pursue federal SBIR dollars 2Wisconsin firms urged to pursue federal SBIR dollars 3Early-stage executives hear from investors 2Early-stage executives hear from investors 3
(Date:7/11/2014)... mesenchymal stem cells can stimulate neurogenesis in the brain ... (AD) and improve tissue and function injury under the ... the therapeutic effect of adipose-derived stem cells (ADSCs) transplantation ... oxidative injury and neurogenesis in the brain of AD ... Life Sciences, Tsinghua University, China transplanted ADSCs into the ...
(Date:7/11/2014)... toxins to study the proteins that let nerve cells ... have stumbled upon a biological tactic that may offer ... in a safe and environmentally responsible way. , ... for one species and harmless for a closely related ... pests without harming beneficial species like bees. A summary ...
(Date:7/10/2014)... BEDFORD, Mass. , June 30, 2014  Aware, ... of biometrics software and services, previously announced on June ... a special cash dividend of $1.75 per share, or ... record date of July 10, 2014 and a payment ... notified by NASDAQ that it had set an ex-dividend ...
Breaking Biology News(10 mins):Potent spider toxin 'electrocutes' German, not American, cockroaches 2Potent spider toxin 'electrocutes' German, not American, cockroaches 3NASDAQ Sets Ex-Dividend Date for Aware, Inc.'s Special Cash Dividend of $1.75 Per Share 2
... This release is available in French . ... the Minister of Industry, on behalf of the Honourable ... the Natural Sciences and Engineering Research Council of Canada ... announced that Nobel Laureate John C. Polanyi is the ...
... have a sizeable biofuels industry based primarily on local ... and new conversion technologies are used, according to a ... Northwest National Laboratory. It will be difficult ... based on todays land use practices with currently available ...
... WINSTON-SALEM, N.C. A small group of patients with ... veins with an injectable microfoam experienced no neurological, visual ... according to preliminary results from a phase II trial. ... Washington, D.C., at the annual scientific meeting of the ...
Cached Biology News:Dr. John Polanyi wins Canada's most prestigious science award 2Key to using local resources for biomass may include waste 2Key to using local resources for biomass may include waste 3Improved foam for varicose veins found to be safe in preliminary results from phase II trial 2
Dual-bay Dyad thermal cycler chassis, does not include the Alpha units (requires 2)...
... dual-bay DNA Engine Dyad thermal cycler ... amplification (PCR). The chassis accommodates a ... heat-pump assemblies), which hold different types ... offers graphical programming with point-and-click navigation. ...
... Red fluorescent RNA stain is used to ... or glyoxal) agarose gels and does not ... a 302 nm transilluminator, the stain emits ... on Polaroid film or with a CCD ...
... The MitoPT kit is used in conjunction ... in culture and induce apoptosis according to your ... cells as a negative control). Once you have ... MitoPT solution to each population and incubate the ...
Biology Products: